Table 4 Progression-free and overall survival in MPC and LAPC cohorts

From: Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

 

Overall survival

Progression-free survival

 

Median OS

6 mo

12 mo

18 mo

Median PFS

6 mo

12 mo

18 mo

Metastatic (37 pts)

10.2 mo

81%

38%

22%

6.1 mo

54%

14%

9%

LAPC (29 pts)

26.6 mo

100%

86%

62%

17.8 mo

97%

69%

62%

  1. Abbreviations: mo, months; Pts, patients.
Back to article page